Mendus Logo

Mendus

Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mendus is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer treatment. The company focuses on preventing tumor recurrence by stimulating the patient's immune system to build active immunity against residual cancer cells. Specializing in allogeneic dendritic cell biology, Mendus aims to improve long-term survival outcomes and preserve the quality of life for cancer patients. Its lead product candidate, vididencel, is under development for various malignancies, including ovarian cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Mendus AB (publ)
Swedish 123.8 KB
2025-11-28 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Mendus AB (publ)
English 123.1 KB
2025-11-18 23:45
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Mendus AB (publ)
Swedish 145.4 KB
2025-11-18 23:45
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Mendus AB (publ)
English 147.5 KB
2025-11-18 23:41
Share Issue/Capital Change
Mendus har framgångsrikt genomfört en riktad nyemission om cirka 52,5 miljoner …
Swedish 151.0 KB
2025-11-18 23:41
Share Issue/Capital Change
Mendus announces successful execution of a directed share issue of approximatel…
English 150.6 KB
2025-11-18 17:31
Share Issue/Capital Change
Mendus avser att genomföra en riktad nyemission av aktier om cirka 50 miljoner …
Swedish 154.0 KB
2025-11-18 17:31
Share Issue/Capital Change
Mendus announces its intention to carry out a directed issue of shares of appro…
English 150.5 KB
2025-11-13 08:00
Quarterly Report
Swedish 1.5 MB
2025-11-13 08:00
Quarterly Report
English 1.5 MB
2025-11-06 08:00
Board/Management Information
Mendus Announces Nomination Committee for the 2026 Annual General Meeting
English 118.1 KB
2025-11-06 08:00
Board/Management Information
Mendus tillkännager valberedning inför årsstämman 2026
Swedish 118.2 KB
2025-10-02 08:00
Regulatory Filings
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
Swedish 138.6 KB
2025-10-02 08:00
Regulatory Filings
Mendus announces updated clinical strategy and operational focus
English 137.5 KB
2025-08-21 08:00
Quarterly Report
Swedish 1.4 MB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mendus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Erik Manting Other Buy 7,780 56,249.40 SEK
2025-03-11 Erik Manting Other Buy 7,780 55,704.80 SEK
2025-02-25 Sven Arne Andreasson Other Buy 25,000 198,750.00 SEK
2024-04-02 Erik Manting Other Other 885,648 425,111.04 SEK
2024-04-02 Dharminder Chahal Other Other 882,048 423,383.04 SEK
2024-04-02 Leopold Bertea Other Other 267,858 128,571.84 SEK
2022-10-25 Sven Arne Andreasson Other Sell 15,000 31,950.00 SEK
2022-10-12 Sven Arne Andreasson Other Sell 10,000 18,800.00 SEK
2022-05-20 Erik Manting Other Buy 37,059 86,347.47 SEK
2022-05-19 Ann-Charlotte Ferm Other Buy 100,000 215,900.00 SEK

Peer Companies

Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.